Hands-On with Dexcom Stelo: An Over-The-Counter Device in the Battle Against Diabetes

As a wearables reviewer, my morning routine has recently changed. Instead of checking my sleep stats on my phone, I now check my glucose levels. The reason for this shift is a new device I have been testing called the Dexcom Stelo continuous glucose monitor (CGM). Unlike traditional CGMs that are mainly used by Type 1 diabetics, the Stelo is specifically designed for Type 2 diabetics who do not rely on insulin. It is one of the three FDA-cleared over-the-counter CGMs available.

Type 2 diabetes is a condition that develops over time as the body becomes more insulin resistant. While some Type 2 diabetics require insulin, the majority manage their blood sugar levels through lifestyle changes and oral medication. The Stelo offers a potential solution for these individuals by providing a tool to monitor and manage their glucose levels effectively, potentially reducing or eliminating the need for medication. This device could also be beneficial for prediabetics, helping them reverse their condition.

However, accessibility and affordability have been significant barriers for CGMs in the past. Health insurance typically does not cover CGMs for individuals who do not take insulin, making them too expensive for the average person. Dexcom aims to address this issue with the Stelo, making it more accessible and affordable. The device can be purchased for $99 for a single pack of two sensors (a 30-day supply) or through a monthly subscription of $89, which includes two sensors delivered every month. Moreover, the Stelo is eligible for Health Savings Account (HSA) and Flexible Spending Account (FSA) reimbursements.

The Stelo works similarly to other CGM-based platforms like Nutrisense, which I tested last year. The device is connected to an app that provides step-by-step instructions for inserting the CGM. Within approximately 30 minutes of calibration, users can view their real-time glucose levels on the app. The Stelo also integrates with iOS and Android health APIs, allowing users to sync their exercise and sleep data. Additionally, users can manually log their meals, and the app sends alerts to their phone if glucose spikes are detected.

Overall, I found the Stelo to be easy to use and the data presentation to be streamlined and user-friendly. However, there were a few limitations and improvements that I identified. One issue was the delay in receiving alerts for glucose spikes, which could be anywhere from 20 to 60 minutes. While this may not be a significant concern for Type 2 diabetics, it could be improved for more immediate feedback. Another area for improvement was the meal logging process. It would be beneficial if users could import their meal information from other apps, streamlining the process and eliminating the need for duplicate entries.

Moreover, I found that the Stelo lacks in providing comprehensive insights and context for interpreting glucose data. The app does not offer long-term historical data, making it challenging to analyze patterns over time. To show my doctor how certain exercises affect my glucose levels, I would need to take a screenshot on that specific day. Additionally, I was uncertain about what constitutes good glucose numbers and had concerns about the number of unexplained glucose spikes I experienced. These limitations highlight the need for additional context and guidance within the app.

Despite these limitations, I believe the Stelo has the potential to be a valuable tool, particularly when used in conjunction with healthcare professionals. As someone with a higher risk of developing diabetes due to a family history of Type 2 diabetes and polycystic ovary syndrome, I found the Stelo’s data to be concerning, prompting me to schedule a doctor’s appointment for further testing. Although the app has its flaws, it is still in the early stages, and improvements can be expected over time. I plan to continue testing the Stelo and look forward to discussing my findings with my doctor.

It is also important to consider how the wider market will respond to more accessible CGMs like the Stelo. There is a growing trend of wellness influencers promoting CGMs for weight loss and metabolic health improvement. However, it is yet to be proven if these devices are truly effective for these purposes. Several startups have emerged based on this premise, but their efficacy and reliability remain uncertain. The future direction of CGMs and their applications will depend on further research and evidence.

In conclusion, I appreciate Dexcom’s efforts to make CGMs more accessible and affordable for individuals managing Type 2 diabetes and prediabetes. While the Stelo has room for improvement, it shows promise as a valuable tool when used in partnership with healthcare professionals. The ability to monitor glucose levels in real-time and track the impact of lifestyle choices on blood sugar can potentially lead to better management of Type 2 diabetes and even reversal of prediabetes. The success and wider acceptance of CGMs in the market will depend on continued innovation, research, and addressing the needs and preferences of users.



Source link